BioSante Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference in London and BioFinance in Toronto.

Business Editors/Health/Medical Writers

BIOWIRE2K

Rodman & Renshaw Techvest Global Healthcare Conference

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--May 6, 2004

BioSante Pharmaceuticals, Inc. (Amex:BPA) announced today that its president and chief executive officer Stephen M. Simes will present at the Rodman & Renshaw Techvest Global Healthcare Conference in London on May 12, 2004 at 8 a.m. London time (3 a.m. EDT). The audio webcast will be available live, then archived for 90 days at: http://www.wallstreetwebcasting.com/webcast/rrshq2/cgpi/.

BioSante also announced that Phillip Donenberg, BioSante's chief financial officer, will be presenting in Toronto at BioFinance Canada, on May 12, 2004 at 4 p.m. EDT.

During their presentations Mr. Simes and Mr. Donenberg will discuss BioSante's hormone therapy products and nanotechnology being developed for improved vaccines and drug delivery. Attendees at the conferences will be key members of the investment community including portfolio managers, analysts, brokers and investment bankers, as well as management of worldwide biotechnology and pharmaceutical companies.

About BioSante Pharmaceuticals, Inc.

BioSante is developing a pipeline of hormone therapy products to treat both men and women. BioSante's hormone therapy products are gel formulations for topical administration that deliver bioidentical estradiol and testosterone. Symptoms treated with hormone therapy in men include impotence, diminished sex drive, muscle weakness and osteoporosis. Symptoms in menopausal women include hot flashes, vaginal atrophy, decreased libido and osteoporosis. The estrogen and testosterone markets in the United States alone account for over $2.5 billion in annual sales. The company also is developing its calcium phosphate nanotechnology (CAP) for novel vaccines, including biodefense vaccines such as anthrax and ricin, and drug delivery systems. Additional information is available online at www.biosantepharma.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding BioSante contained in this press release that are not historical in nature, particularly those that utilize terminology such as "may," "will," "should," "likely," "expects," "anticipates," "estimates," "believes" or "plans," or comparable terminology, are forward-looking statements. Forward-looking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to BioSante that cause actual results to differ materially from those expressed in such forward-looking statements are the difficulty of developing pharmaceutical products and especially of new vaccines, obtaining regulatory and other approvals and achieving market acceptance, and other factors identified and discussed from time to time in BioSante's filings with the Securities and Exchange Commission, including those factors discussed on pages 18 to 25 of BioSante's Form 10-KSB, which discussion also is incorporated herein by reference.

For more information, please contact: Phillip B. Donenberg, CFO: [e-mail]